Share on StockTwits

Analysts at Needham & Company LLC dropped their price objective on shares of Amedica (NASDAQ:AMDA) from $13.00 to $11.00 in a research report issued to clients and investors on Friday, Stock Ratings News reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 79.74% from the stock’s previous close.

Shares of Amedica (NASDAQ:AMDA) opened at 6.12 on Friday. Amedica has a 1-year low of $5.30 and a 1-year high of $9.37. The stock has a 50-day moving average of $6.96 and a 200-day moving average of $7.14. The company’s market cap is $75.3 million.

Amedica (NASDAQ:AMDA) last released its earnings data on Thursday, May 15th. The company reported ($0.78) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.31) by $0.47. The company had revenue of $5.78 million for the quarter, compared to the consensus estimate of $5.95 million. Analysts expect that Amedica will post $-1.13 EPS for the current fiscal year.

Separately, analysts at JMP Securities initiated coverage on shares of Amedica in a research note on Thursday, March 6th. They set an “outperform” rating on the stock.

Amedica Corporation (NASDAQ:AMDA) is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.